abstract231 - MONOCYTE CHEMOTACTIC PROTEIN-1 (MCP-1) URINARY LEVEL IN PATIENTS WITH OVERACTIVE BLADDER (OAB) BEFORE AND AFTER TREATMENT: PILOT PROSPECTIVE STUDY
MONOCYTE CHEMOTACTIC PROTEIN-1 (MCP-1) URINARY LEVEL IN PATIENTS WITH OVERACTIVE BLADDER (OAB) BEFORE AND AFTER TREATMENT: PILOT PROSPECTIVE STUDY
J. PALMER1, B. FARHAN 2, A. AHMED 1, K. BETTIR 1, G. GHONIEM 3;
1Urology, Univ. of California Irvine, Orange, CA, 2Urology, Univ. Of California,Irvine, Orange, CA, 3Univ. of California, Irvine, Orange, CA.
Introduction: Urinary cytokines have been previously tested which showed elevated levels due to inflammation and/or urothelial dysfunction. This study aims to express urinary MCP-1 level in OAB patients before and after treatments, and to correlate the level of MCP-1 with severity of symptoms.
Objective: This study aims to express urinary MCP-1 level in OAB patients before and after treatments, and to correlate the level of MCP-1 with severity of symptoms.
Methods: This was a prospective, single-blind study including 26 OAB patients (either newly diagnosed or off medications for 2 weeks). Each patient received after the first visit different OAB treatments (anticholinergic, B3 agonist and or neuromodulations). Two midstream urine samples were collected and tested for MCP-1 using ELISA; one before and the second after 12 weeks of treatments. Symptomatic responses to therapy were evaluated using different validated OAB questionnaires [Patient Perception Bladder Condition (PPBC) & Overactive Bladder Quality (OAB-q)]. MCP-1 level adjusted by urinary creatinine. Descriptive statistics were performed to examine MCP-1 level before and after different. Post-treatment MCP1- levels aja compared to 12 The MCP-1 level after Also a comparison between the (MPC-1) level after treatment and control group was done.
Results: A total of 28 patients underwent different OAB treatments. The mean age of enrolled patients was 69.3. Males accounted for 37.5% of patients and females accounted for 62.5% of patients. All 28 patients reported improvement of symptoms in varying degrees. Wilconxon test used to compare between (MPC-1) level pre-treatment and post-treatment groups with P<.000 (Tab1). Mann-Whitney U test used to compare between (MPC-1) level post-treatment and control groups with P =0.376 (Tab1). There is moderate association between symptom and pre-treatment (MCP-1) (Fig1). In simple correlation, MCP was significantly associated with OABq (coefficient=.869, p<.000) and PP (coefficient=.844, p<.000). In multiple linear regression using age, gender and MCP -1, MCP- 1was associated with OABq (p=.02) and PP (p=.03).
Conclusions: Based on our result (MPC-1) can be used as a predictor of OAB syndrome and can be used in the follow up of the treatment and monitoring of the prognosis.